Home/Filings/4/0001140361-23-028539
4//SEC Filing

Devroe Eric 4

Accession 0001140361-23-028539

CIK 0001781174other

Filed

Jun 5, 8:00 PM ET

Accepted

Jun 6, 4:15 PM ET

Size

17.1 KB

Accession

0001140361-23-028539

Insider Transaction Report

Form 4
Period: 2023-06-05
Devroe Eric
Chief Operating Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-06-05$1.04/sh+9,225$9,59462,883 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-06-059,22596,615 total
    Exercise: $1.04Exp: 2031-01-13Common Stock (9,225 underlying)
Footnotes (1)
  • [F1]Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2021, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Issuer

Acrivon Therapeutics, Inc.

CIK 0001781174

Entity typeother

Related Parties

1
  • filerCIK 0001950573

Filing Metadata

Form type
4
Filed
Jun 5, 8:00 PM ET
Accepted
Jun 6, 4:15 PM ET
Size
17.1 KB